Pharmaceutical Manufacturing and Exports, Research and Development in Pharma, pharma china.#Pharma #china


Posted On May 17 2018 by

pharma china

Pharma china

THROUGH TRUST

SINGLE PRODUCT FILED IN 25 COUNTRIES

Pharma china

THROUGH GROWTH

40% TOPLINE GROWTH IN THE LAST 4 YEARS

Pharma china

THROUGH PARTNERSHIP

ASSOCIATED WITH THE UNO FOR DEVELOPMENT OF ARVS

Pharma china

THROUGH CAPABILITY

4900 KL REACTION CAPABILITY, 55 TYPES OF REACTION

Pharma china

AUROBINDO’S WORKFORCE IS MAKING TOMORROW POSSIBLE

OVER 14500 EMPLOYEES FROM 26 COUNTRIES

Pharma chinaAurobindo is one of the top API manufacturing companies.. Read More

formulations

Pharma chinaFormulations One of the largest vertically in. Read More

Custom Synthesis

Pharma chinaCustom Synthesis AuroSource is the Custom. Read More

ARVs / HIVs

Pharma chinaWe aim to achieve the goals for wider access. Read More

PEPTIDES

Pharma chinaAuro Peptides Ltd. is the subsidiary division of. Read More

Nutraceuticals

AUROZYMES

Pharma chinaAuroZymes is the biocatalysis division . Read More

Pharma chinaResearch and Development Aurobindo’s R D strengths are in . Read More

STRATEGIC ALLIANCE

Pharma china

Aurobindo has evolved into a knowledge driven. Strategic Alliance

SOCIAL RESPONSIBILITY

Pharma china

Our Corporate Social Responsibility includes. Social Responsibility

GLOBAL FAMILY

Pharma china

Aurobindo Pharma has a team of more than. Global Family

INVESTOR RELATIONS

Pharma china

Financial Results of Aurobindo Pharma. Investor Relations

Global leadership position In Anti-infectives

Among the largest ‘ Vertically Integrated ‘ pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs Formulations

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.

Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Market Watch

News corner

Mile stones

Significant milestones in Aurobindo’s journey towards enriching lives worldwide.

1988 – Started off with one SSP Unit

Mile stones

  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china
  • Pharma china

Last Updated on: May 17th, 2018 at 4:03 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *